This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): R3502, RG3502, RO5304020, Trastuzumab-MCC-DM1, T-DM1, Herceptin-DM1, Trastuzumab-DM1 (TDM-1)
Revenue splits are BioMedTracker estimates.
Trastuzumab-DM1 is comprised of Immunogen's DM1 linked to Genentech’s therapeutic antibody, trastuzumab. Trastuzumab targets overexpression of the HER2 protein. DM1 is a derivative of maytansine and a potent inhibitor of cell division.
Genentech and ImmunoGen
In May 2000, Genentech licensed the exclusive worldwide right to use Immunogen's maytansinoid TAP technology with antibodies that target HER2, as well as a five-year agreement with ImmunoGen that enables Genentech to test ImmunoGens TAP technology with a limited number of its antibodies. ImmunoGen received a $3 million upfront payment upon the signing of this agreement.
Under this agreement, the deal terms of each product license that Genentech takes include upfront and potential milestone payments totaling nearly $40 million as well as mid-single digit royalties on net product sales. ImmunoGen is to be reimbursed for any preclinical and clinical materials that it manufactures under this agreement. Genentech is responsible for product development, manufacturing and commercialization.
In May 2005, Genentech exercised its option to renew this agreement for one subsequent three-year period, paying $2 million to ImmunoGen to renew this agreement. In...See full deal structure in Biomedtracker
Partners: Chugai Pharmaceutical Co., Ltd. PDL BioPharma, Inc. Endo International plc
Additional information available to subscribers only: